echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: Low rates of somatic NLRC4 mutations cause late-onset autoinflammatory disease

    ARD: Low rates of somatic NLRC4 mutations cause late-onset autoinflammatory disease

    • Last Update: 2022-08-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Objective: Germline gain-of-function mutations in NLRC4 are known to be associated with autoinflammation in infantile enterocolitis/recurrent macrophage activation syndrome or familial cold autoinflammatory syndrom.


    Methods: A research team from Zhejiang University performed whole-exome/genome sequencing and digital droplet PCR (ddPCR) to identify pathogenic somatic mutation.


    Results: We identified a somatic mutation in NLRC4 (.


    Conclusions: This study reports a case of late-onset autoinflammatory disease caused by somatic NLRC4 mutations in a small subset of leukocyte.


    Source: Wang J, Ye Q, Zheng W, et a.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.